Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association

No abstract is available for this paper.

• Publication year

  2018

• Venue

  The Journal of Korean Diabetes

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4093/JKD.2018.19.1.15
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017:a Position Statement of the Korean Diabetes Association

  2018cited by this paper
• Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium

  2017cited by this paper
• Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　- Results From EMPA-REG OUTCOME®.

  2017cited by this paper
• Monotherapy in patients with type 2 diabetes mellitus

  2017cited by this paper
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association

  2017cited by this paper
• Cardiovascular and non‐cardiovascular safety of dipeptidyl peptidase‐4 inhibition: a meta‐analysis of randomized controlled cardiovascular outcome trials

  2016cited by this paper
• Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes

  2016cited by this paper
• Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials.

  2016cited by this paper
• Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials

  2016cited by this paper
• Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.

  2016cited by this paper
• Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.

  2016cited by this paper
• Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials

  2016cited by this paper
• Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes

  2015cited by this paper
• Behavioral Programs for Type 2 Diabetes Mellitus

  2015cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

  2014cited by this paper
• Global guideline for type 2 diabetes.

  2014cited by this paper
• Pharmacologic management of type 2 diabetes.

  2013cited by this paper
• Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

  2013influential reference
• Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

  2013cited by this paper
• Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial--clinical implications.

  2011cited by this paper
• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

  2011cited by this paper
• Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study

  2011cited by this paper
• Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials

  2011cited by this paper
• The Effect of Oral Antidiabetic Agents on A1C Levels

  2010cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

  2009cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Efficacy and Safety of Mitiglinide in Korean Type 2 Diabetic Patients: Prospective Randomised Multicenter Comparative Phase III Study

  2007cited by this paper
• Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective.

  2007cited by this paper
• Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy

  2006cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence

  2001cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper

• Anti-diabetic effects of aqueous extract of Dendropanax morbifera Lev. leaves in streptozotocin-induced diabetic Sprague-Dawley rats

  2021cites this paper